Tandem Diabetes Care (TNDM) Could Be 23% Below Fair Value After Q2 Results
Tandem Diabetes Care has seen a significant share price increase following strong second-quarter 2026 results that featured record sales and improved margins. Analysts suggest the company may still be undervalued despite recent gains, driven by growth in pharmacy-based supply sales.
Why it matters
Investors are evaluating whether medical device companies can sustain growth through recurring revenue models in a shifting healthcare landscape.
Tandem Diabetes Care (TNDM) Could Be 23% Below Fair Value After Q2 Results Tandem Diabetes Care (TNDM) Could Be 23% Below Fair Value After Q2 Results · Simply Wall St. Simply Wall St Sat, 8 August 2026 at 10:07 pm GMT-4 2 min read TNDM +19.11% Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
Tandem Diabetes Care (TNDM) is back in focus after reporting second quarter 2026 results that paired record worldwide sales and a smaller net loss with reaffirmed full year sales guidance.
See our latest analysis for Tandem Diabetes Care.
The strong second quarter update has coincided with a sharp reversal in sentiment around Tandem Diabetes Care, with a 45.61% 1 month share price return and a 99.29% 1 year total shareholder return, even though the 3 year total shareholder return remains down 21.31%.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in